Generali backs Italian stem cell trial
Italian insurer Generali and research organisation Associazione Revert Onlus have begun a three-year partnership to support cell therapy clinical trial on Amyotrophic Lateral Sclerosis.
The goal of the partnership is to allow the Revert team to complete the trial by autumn to later extend it to other neurological and neurodegenerative diseases.
Cell therapy clinical trial on ALS
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: http://subscriptions.postonline.co.uk/subscribe
You are currently unable to print this content. Please contact info@postonline.co.uk to find out more.
You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@postonline.co.uk
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@postonline.co.uk
Most read
- Esure offers customers six-months free cover for latest tech glitch
- Big Interview: Jason Storah, Aviva
- Copart confirms delays to Luton Airport salvage operation